Shengbao Biotechnology Co., Ltd. was established in 2023 and is headquartered in Shenzhen, China. The company is committed to developing innovative live bacterial drugs, utilizing gene circuits and precise regulation of gene and payload expression to meet the treatment needs of various types of diseases. Shengbao Biotechnology currently focuses on the research and development of live bacteria drugs in the field of solid tumor treatment. With its unique mechanism understanding and advanced quantitative synthetic biology technology, it aims to develop anti-tumor live bacteria drugs that are safe, efficient, broad-spectrum, targeted, and non-invasive.